πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8389228

Process for the measurement of the potency of glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8383645

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8367106

Compressed solid dosage form manufacturing process well-suited for use with drugs of low a

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Feb 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8367105

Compressed solid dosage form manufacturing process well-suited for use with drugs of low a

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Feb 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8338396

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Dec 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8334409

Process for purifying rasagiline base

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8329696

Solid state forms of sitagliptin salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Dec 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8323634

Stable formulations of highly concentrated recombinant human albumin-human granulocyte col

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8323679

Flexible, compressed intravaginal rings, methods of making and using the same, and apparat

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8288342

Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low do

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8252933

2-oxo-1,2-dihydro-quinoline modulators of immune function

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Aug 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8247393

Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Aug 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8226977

Pharmaceutical composition containing irbesartan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Jul 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8226980

Orally disintegrating solid dosage forms comprising progestin and methods of making and us

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Jul 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8222282

Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine

Teva Pharmaceuticals USA, Inc. Β· Granted Tue Jul 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8217024

Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Jul 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8207361

Tigecycline crystalline forms and processes for preparation thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Jun 26 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8202534

Attachment of a handle to a solid oral dosage form

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8198470

Crystalline form II of tigecycline and processes for preparation thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8198469

Crystalline forms of tigecycline and processes for preparation thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8188067

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8188149

Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8183373

Solid state forms of sitagliptin salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8178127

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted